Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN Trial

Diabetes Care

Volumn 38, Issue 1, 2015, Pages 22-28

  Riddle, Matthew C ^a   Gerstein, Hertzel C ^b   Jung, Hyejung ^b   Mellbin, Linda G ^c   Rydén, Lars ^c   Rosenstock, Julio ^d   Probstfield, Jeffrey ^e  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HEMOGLOBIN A1C; INSULIN GLARGINE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; ANTIDIABETIC AGENT; GLARGINE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; LONG ACTING INSULIN; SULFONYLUREA DERIVATIVE;

AGE; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSGLYCEMIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; PREDICTION; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); BLOOD; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; METABOLISM; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CREATININE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 84920023912     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1329     Document Type: Article

References (20)

1. Zoungas S, Patel A, Chalmers J, et al.; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410-1418
2. Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care 2011;34(Suppl. 2):S132-S137
3. Yakubovich N, Gerstein HC. Serious cardiovascular outcomes in diabetes: The role of hypoglycemia. Circulation 2011;123:342-348
4. Mellbin LG, Malmberg K, Waldenstrom A, Wedel H, Ryden L. for the DIGAMI 2 investigators. Prognostic implications of hypoglycaemic episodes during hospitalization for myocardial infarction in patients with type 2 diabetes: A report from the DIGAMI 2 trial. Heart 2009;95: 721-727
5. Kong APS, Yang X, Luk A, et al. Severe hypoglycemia identifies vulnerable patients with type 2 diabetes at risk for premature death and all-site cancer: The Hong Kong diabetes registry. Diabetes Care 2014;37:1024-1031
6. Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J; Origin Trial Investigators. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008;155: 26-32, e1-e6
7. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-328
8. Mellbin LG, Ryd én L, Riddle MC, et al.; ORIGIN Trial Investigators. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 2013;34: 3137-3144
9. ORIGIN Trial Investigators. Characteristics associated with maintenance of mean A1C,6.5% in people with dysglycemia in the ORIGIN trial. Diabetes Care 2013;36:2915-2922
10. Frick U, Frick H, Langguth B, Landgrebe M, Hübner-Liebermann B, Hajak G. The revolving door phenomenon revisited: Time to readmission in 17'145 [corrected] patients with 37'697 hospitalisations at a German psychiatric hospital. PLoS One 2013;8:e75612
11. Karl DM, Gill J, Zhou R, Riddle MC. Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15:622-628
12. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001;161:1653-1659
13. Leese GP, Wang J, Broomhall J, et al.; DARTS/MEMO Collaboration. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: A populationbased study of health service resource use. Diabetes Care 2003;26:1176-1180
14. Davis TME, Brown SGA, Jacobs IG, Bulsara M, Bruce DG, Davis WA. Determinants of severe hypoglycemia complicating type 2 diabetes: The Fremantle diabetes study. J Clin Endocrinol Metab 2010;95:2240-2247
15. Miller ME, Bonds DE, Gerstein HC, et al.; ACCORD Investigators. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010;340:b5444
16. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009;301: 1565-1572
17. Bruderer SG, Bodmer M, Jick SS, Bader G, Schlienger RB, Meier CR. Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes patients in the UKda nested case-control analysis. Diabetes Obes Metab 2014;16:801-811
18. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: Retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909
19. Seaquist ER, Miller ME, Bonds DE, et al.; ACCORD Investigators. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care 2012;35:409-414
20. Riddle MC, Ambrosius WT, Brillon DJ, et al.; Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010; 33:983-990